Lipella Pharmaceuticals

Lipella Pharmaceuticals is a pharmaceutical company focused on developing and commercializing innovative liposomal drug delivery systems for mucosal surfaces. They are headquartered in Pittsburgh, Pennsylvania and specialize in addressing the unmet needs of cancer survivors, particularly those experiencing radiation cystitis and hemorrhagic cystitis. Their mission is to improve the lives of patients by developing safe and effective treatments that reduce the incidence and severity of these complications.

Lipella Pharmaceuticals has a robust pipeline of drug candidates in various stages of development, including LP-10 for hemorrhagic cystitis and LP-50 for non-muscle invasive bladder cancer. They are actively engaged in clinical trials and have successfully completed Pre-IND meetings with the FDA. Lipella Pharmaceuticals is committed to advancing their research and clinical programs to bring their innovative therapies to market and provide meaningful benefits to patients.

Lipella Pharmaceuticals is a company focused on developing and delivering innovative treatments for patients with debilitating and often rare mucosal diseases. They are committed to empowering cancer survivorship and improving the quality of life for patients with oral lichen planus, radiation cystitis, and other mucosal conditions.

Lipella Pharmaceuticals promotes a culture focused on scientific advancement and patient well-being. Their commitment to developing innovative treatments for underserved patient populations like cancer survivors is evident in their research and development efforts, particularly their focus on liposomal drug delivery and their establishment of a radiation cystitis patient registry.